title: [Guidelines on long-acting injectable atypical antipsychotics for first-episode schizophrenia].
abstract: The current review raises the question of the place of long-acting injectable (LAI) atypical antipsychotics for the treatment of first-episode schizophrenia in current and future guidelines. After exposing the different points of view adopted in the former, the author presents the clinical trials conducted with LAI atypicals in this indication, as well as the surveys related to psychiatrists'opinion regarding the use of these drugs in early schizophrenia. Pros and cons of this therapeutic option are discussed and suggestions are made for further guidelines.
authors.affiliation: SHU Psychiatrie adultes-Pavillon Solaris, Hôpital Sainte-Marguerite, 13274 Marseille, Cedex 09, France. Electronic address: jazorin@ap-hm.fr.
authors.forename: J-M
authors.initials: JM
authors.lastname: Azorin
mesh_terms: D000465:Algorithms; D014150:Antipsychotic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001291:Attitude of Health Personnel; D002986:Clinical Trials as Topic; D003692:Delayed-Action Preparations; D019983:Guideline Adherence; D007273:Injections, Intramuscular; D055118:Medication Adherence / Q000523:psychology; D017410:Practice Guidelines as Topic; D011788:Quality of Life / Q000523:psychology; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D055502:Secondary Prevention; D012917:Social Adjustment
chemical_list: D014150:Antipsychotic Agents; D003692:Delayed-Action Preparations
keywords: Antipsychotiques atypiques injectables d’action prolongée; Early schizophrenia; First-episode schizophrenia; Guidelines; Long-acting injectable atypical antipsychotics; Premier épisode psychotique; Recommandations; Schizophrénie débutante